2016 / 04

DOI: 10.24075/brsmu.2016-04-10

ORIGINAL RESEARCH

Trophic changes in the skeletal muscles of rats after therapy with sildenafil and cerebrolysin in the lower limb ischemia model

Belous AS1,2, Biryukova YuK1, Zatolokina MA2, Lavrinenko KI2, Loyko EA2, Mal GS2, Shevelev AB1, Trubnikova EV1
About authors

1 Research Laboratory “Genetics”,
Kursk State University, Kursk, Russia

2 Kursk State Medical University, Kursk, Russia

Correspondence should be addressed: Ekaterina Loyko
19 Stepnoy pereulok, d. 14, Kursk, Russia, 305025; ur.xednay@noom.nyrtak

About paper

Acknowledgements: authors thank professor Victor Lazarenko (Kursk State Medical University) and professor Alexandr Khudin (Kursk State University) for providing research facilities for the experiment.

Received: 2016-08-20 Accepted: 2016-08-27 Published online: 2017-01-05
|
  1. Tkachuk VA, Bochkov VN, Philippova MP, Stambolsky DV, Kuzmenko ES, Sidorova MV, et al. Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as T-cadherin. FEBS Lett. 1998 Jan 16; 421 (3): 208–12. PubMed PMID: 9468307.
  2. Kirichenko AA, Novichkova N. Khronicheskaya ishemicheskaya bolezn’ nog. Moscow; 1998. 24 p. Russian.
  3. Pokrovsky MV, Kolesnik IM, Chodov SV, Intercession TG, Dolzhikov AA, Ephremenkova DA, et al., inventors; Kursk State Medical University, assignee. Sposob farmakologicheskoy korrektsii ishemii skeletnoy myshtsy sildenafilom, v tom chisle pri I-name-indutsirovannom defitsite oksida azota. Patent RU 2497203. 2013 Oct 27. Russian.
  4. Knyazev VV. Mikroskopicheskoe issledovanie reparativnoy regeneratsii nervnykh volokon posle khimicheskoy desimpatizatsii. In: Universitetskaya nauka: Vzglyad v budushchee. Sbornik trudov 72 nauchnoy konferentsii KGMU i sessii Tsentral'no-Chernozemnogo nauchnogo tsentra RAMN. Rossiyskiy simpozium «Zakonomernosti integratsii fiziologicheskikh funktsiy v norme i ikh dezintegratsiya v patologii»; 2007 Feb 1–2; Kursk, Russia. Vol. 1. Kursk: KGMU; 2007. p. 116–9. Russian.
  5. Kovalenko V, Kalitko I, Temrezov M, Chemurziev R, Petrov A. Vozmozhnosti lecheniya bol'nykh s aterotromboticheskim porazheniem arteriy nizhnikh konechnostey. Vrach. 2010; (3): 55–8. Russian.
  6. Sepiashvili RI, Shubich MG, Karpyuk VB. Oksid azota pri astme i razlichnykh formakh immunopatologii. Astma. 2009; 2 (2): 5–14. Russian.
  7. Chervyakov YuV, Staroverov IN, Nersisyan EG, Isaev AA, Deev RV. [Therapeutic angiogenesis in treatment of patients with chronic obliterating diseases of lower limb arteries]. Angiology and Vascular Surgery. 2012. 18 (3): 19–27. Russian.
  8. Rowe VL, Lee W, Weaver FA, Etzioni D. Patterns of treatment for peripheral arterial disease in the United States: 1996–2005. J Vasc Surg. 2009 Apr; 49 (4): 910–7.
  9. Gorchakov VD, Sergienko VI, Vladimirov VG. Selektivnye gemosorbenty. Moscow: Meditsina; 1989. 221 p. Russian.
  10. Pokrovskaja TG, Chuljukova TN, Pokrovskii TV [Endothelioprotective effects of sildenafil and tadalafil at experimental model of the I-name-induced deficiency of nitric oxide]. Kubanskii nauchnyi meditsinskii vestnik. 2009. 4: 136–9. Russian.
  11. Pokrovskaya TG, Chulyukova TN, Pokrovskiy MV, Filippenko NG. Endotelioprotektivnye dozozavisimye effekty sildenafila v kombinatsiyakh s L-argininom pri eksperimental'nom modelirovanii L-NAME-indutsirovannogo defitsita oksida azota. Biomedicine. 2010. 1 (5): 118–20. Russian.
  12. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc.). 2012. 48 Suppl A: 3–24.
  13. González ME, Francis L, Castellano O. Antioxidant systemic effect of short-term Cerebrolysin administration. J Neural Transm Suppl. 1998. 53: 333–41.
  14. Sugita Y, Kondo T, Kanazawa A, Itou T, Mizuno Y. [Protective effect of FPF 1070 (cerebrolysin) on delayed neuronal death in the gerbil-detection of hydroxyl radicals with salicylic acid]. No To Shinkei. 1993. 45 (4): 325–31. Japanese.
  15. EVER Neuro Pharma. Cerebrolysin — product monograph. 2010. 84 p.
  16. Gambaryan PP, Dukelskaya NM. Krysa. Moscow: Sovetskaya nauka; 1955. 254 p. Russian.
  17. Artyushkova EB, Pashkov DV, Pokrovsky MV, Faitelson AV, Gudyrev OS, Pokrovskaya TG, et al. [Possibilities of pharmacological correction of experimental chronic limb ischemia]. Éksperimentalnaya i Klinicheskaya Farmakologiya. 2008; 71 (3): 23–5. Russian.
  18. Young W, Keck WM. Tserebrolizin: obzor klinicheskikh i eksperimental'nykh issledovaniy. Prakticheskaya angiologiya [Internet]. 2009 [cited 2016 Sep 1]; 8 (27): [about 8 p.]. Available from: http://angiology.com.ua/ru-issue-article-273. Russian.
  19. Kolesnik IM, Lasarenko VA Pokrovskiy MV. [The influence of pharmacological preconditioning with sildenafil and vardenafil on condition of microvasculature in the ischemic skeletal muscle]. Kursk Scientific and Practical Bulletin "Man and His Health". 2015; (1): 83–6. Russian.
  20. Beyer S, Speich R, Fischler M, Maggiorini M, Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly. 2006 Feb 18; 136 (7–8): 114–8.
  21. Das S, Maulik N, Das DK, Kadowitz PJ, Bivalacqua TJ. Cardioprotection with sildenafil, a selective inhibitor of cyclic 3',5'-monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res. 2002; 28 (6): 213–9.
  22. Vertkin AL. Klinicheskaya farmakologiya ingibitorov FDE 5: vzglyad klinicheskogo farmakologa. Consilium medicum. 2004; 6 (7): 502–5. Russian.
  23. Alvarez XA, Lombardi VR, Fernández-Novoa L, Garciá M, Sampedro C, Cagiao A, et al. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J Neural Transm. Suppl. 2000; 59: 281–92.
  24. Lombardi VR, Windisch M, García M, Cacabelos R. Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp Clin Pharmacol. 1999; 21 (5): 331–8.